

Date: August 08, 2024

To, The Manager, Listing Department, National Stock Exchange of India Limited (NSE), Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, BSE Limited, 1 st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
Symbol – LINCOLN	Scrip Code – 531633

Dear Sir,

SUB.: OUTCOME OF BOARD MEETING.

Further to our intimation dated July 30, 2024, Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, August 08, 2024, have considered/approved/recommended, inter alia, the followings: -

1. The un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2024 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter ended on June 30, 2024. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, we enclose herewith financial highlights for the aforesaid quarter.

Meeting of the Board of Directors commenced at 10:30 A.M and concluded at 12:00 P.M.

Kindly take the same on your records.

Thanking you,
Yours faithfully,

For Lincoln Pharmaceuticals Limited




Trusha Shah
Company Secretary & Compliance Officer

Encl: A/a

Regd. Office : "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.

Phone : +91-79-4107 8000 | CIN L24230GJ1995PLC024288

E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com



LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,

Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2024.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		Year Ended			
		30/06/2024 (Un-Audited)	31/03/2024 Refer No. 3	30/06/2023 (Un-Audited)	31/03/2024 (Audited)
1	Income				
	A) Revenue From Operations	14,728.18	14,249.30	13,561.95	58,054.96
	B) Other Income	1,040.92	701.91	769.08	3,442.25
	Total Income (1)	15,769.10	14,951.21	14,331.03	61,497.21
2	Expenses				
	A) Cost of Material Consumed	5,274.56	5,188.72	4,269.53	20,112.45
	B) Purchase of Stock-In-Trade	1,333.07	1,700.17	1,544.11	8,291.48
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	416.23	468.83	570.77	(570.06)
	D) Employee Benefits Expenses	2,901.99	2,505.26	2,647.02	10,289.96
	E) Finance Costs	43.91	49.91	41.46	146.26
	F) Deprecation and Amortisation Expense	322.43	268.58	254.53	1,062.47
	G) Other Expenses	2,529.12	2,548.02	2,458.95	9,940.39
	Total Expenses (2)	12,821.31	12,729.49	11,786.37	49,272.95
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,947.79	2,221.72	2,544.66	12,224.26
4	Exceptional Items	Nil	Nil	Nil	Nil
5	Profit / (Loss) after Exceptional items but Before Tax (3-4)	2,947.79	2,221.72	2,544.66	12,224.26
6	Tax Expense				
	A) Current Tax	551.30	387.50	551.00	2,520.50
	B) Deferred Tax	29.32	(49.28)	92.32	349.48
	C) Short / (Excess) Tax Provision	Nil	23.79	Nil	23.79
7	Net Profit / (Loss) For The Period (5-6)	2,367.17	1,859.71	1,901.34	9,330.49
8	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	1.53	28.44	(7.44)	6.11
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
9	Total Comprehensive Income	2,368.70	1,888.15	1,893.90	9,336.60
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity				57,280.62
12	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)				
	(a) Basic	11.82	9.28	9.49	46.58
	(b) Diluted	11.82	9.28	9.49	46.58

NOTES:

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2024 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 08, 2024. The auditor have carried out an limited review of the said financial results.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2024 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel

Sd/-

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 08, 2024

SAMIR M. SHAH & ASSOCIATES

Chartered Accountants

"Heaven", 8, Western Park Society, Nr. Inductotherm,
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors of,
Lincoln Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended June 30, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The Statement includes the results for the quarter ended 31st March 2024 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2024 and the unaudited year-to-date figures upto 31st December 2023 which were subjected to a limited review.

2. Management's Responsibility for the statement:

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. Auditor's Responsibility:

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Conclusion:

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 08/08/2024

For, Samir M Shah & Associates

Chartered Accountants

Firm Registration No. 122377W

Samir M Shah

Samir M Shah

Partner

Membership No. 111052

UDIN: 24111052BKBQWR8436



LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,

Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2024.

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30/06/2024 (Un-Audited)	31/03/2024 Refer No. 3	30/06/2023 (Un-Audited)	Year Ended 31/03/2024 (Audited)
1	Income				
	A) Revenue From Operations	14,728.18	14,249.30	13,561.95	58,054.96
	B) Other Income	1,040.92	701.91	769.08	3,442.25
	Total Income (1)	15,769.10	14,951.21	14,331.03	61,497.21
2	Expenses				
	A) Cost of Material Consumed	5,274.56	5,188.72	4,269.53	20,112.45
	B) Purchase of Stock-In-Trade	1,333.07	1,700.17	1,544.11	8,291.48
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	416.23	468.83	570.77	(570.06)
	D) Employee Benefits Expenses	2,901.99	2,505.26	2,647.02	10,289.96
	E) Finance Costs	43.91	49.92	41.68	146.49
	F) Depreciation and Amortisation Expense	322.43	268.58	254.53	1,062.47
	G) Other Expenses	2,529.12	2,548.02	2,458.73	9,940.16
	Total Expenses (2)	12,821.31	12,729.50	11,786.37	49,272.95
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,947.79	2,221.71	2,544.66	12,224.26
4	Exceptional Items	Nil	Nil	Nil	Nil
5	Profit / (Loss) after Exceptional items but Before Tax (3-4)	2,947.79	2,221.71	2,544.66	12,224.26
6	Tax Expense				
	A) Current Tax	551.30	387.50	551.00	2520.50
	B) Deferred Tax	29.32	(49.28)	92.32	349.48
	C) Short / (Excess) Tax Provision	Nil	23.79	Nil	23.79
7	Net Profit / (Loss) For The Period (5-6)	2,367.17	1,859.70	1,901.34	9,330.49
8	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	1.53	28.44	(7.44)	6.11
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
9	Total Comprehensive Income	2,368.70	1,888.14	1,893.90	9,336.60
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity				57,280.62
12	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)				
	(a) Basic	11.82	9.28	9.49	46.58
	(b) Diluted	11.82	9.28	9.49	46.58

NOTES:

- The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2024 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 08, 2024. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2024 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated Results includes results of its subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel

Sd/-

Mahendra G. Patel
Managing Director

DIN: 00104706

Place: Ahmedabad

Date: August 08, 2024

